Financial Data and Key Metrics Changes - In 2025, the company generated $1.4 billion in consolidated revenue, with a record adjusted EBITDA of $260 million, despite a challenging macro environment [17][25] - The company improved consolidated margins and achieved a gross profit margin of 54% in Q4 2025 [18][22] - Adjusted EBITDA for Q4 2025 was $64.2 million, exceeding guidance [25] Business Line Data and Key Metrics Changes - The Water Infrastructure segment saw revenue growth of over 800% over five years, becoming the largest segment by profitability [8] - The Chemical Technology segment achieved 19% year-over-year revenue growth and 45% growth in gross profit before depreciation and amortization [13][24] - The Water Services segment maintained market-leading positions and achieved 7% revenue growth in Q4 2025 [20][23] Market Data and Key Metrics Changes - The company anticipates a steady commodity price environment in 2026, with oil prices expected to remain between $55-$65 [17] - The company expects 20%-25% year-over-year growth in the Water Infrastructure segment for 2026 [9][21] Company Strategy and Development Direction - The company is focusing on expanding its water infrastructure in the Northern Delaware Basin, which is characterized by productive geology and low breakevens [9][10] - Strategic investments are being made in long-term diversification efforts, including beneficial reuse and mineral extraction [7][12] - The company aims to grow its water infrastructure to account for over 60% of consolidated gross profit in the next 24 months [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for 2026, supported by ongoing infrastructure projects and market demand [16][30] - The company is well-positioned to generate healthy and durable free cash flows over the long term, with a focus on capital allocation for growth and shareholder returns [30] Other Important Information - The company is exploring additional opportunities in lithium extraction and other high-margin revenue streams [44][45] - The Peak Rentals business is under strategic evaluation to maximize value for shareholders while supporting core water infrastructure growth [15][50] Q&A Session Summary Question: Expansion opportunities in Northern Delaware - Management noted a mix of smaller opportunities and some larger projects in the Northern Delaware, with a focus on leveraging the existing system for attractive returns [32][34] Question: Future growth for infrastructure business - Management indicated ongoing expansion in Lea and Eddy County, with potential for growth into other basins [37] Question: Lithium extraction partnerships - Management confirmed ongoing evaluations for additional high-margin opportunities, including iodine and strontium extraction [44][45] Question: Update on Peak Rentals business - Management is strategically engaging around Peak Rentals to ensure positive outcomes for both Peak and Select [46][50] Question: Beneficial reuse pilots - Management highlighted successful pilots in collaboration with operators and universities, focusing on treated produced water for agricultural applications [53][56]

Core Insights - Telescope Innovations Corp. reported Q1 financial results for the fiscal quarter ended November 30, 2025, with revenues of CAD 2.7 million, a significant increase from CAD 1.2 million in Q1 FY2025, driven by product sales and new service offerings [1][5] - The company experienced an adjusted EBITA loss of CAD 829,000, compared to a loss of CAD 100,000 in the previous fiscal year [5] - The financial results align with management's budget expectations and FY 2026 targets, indicating a strategic reinvestment in operational growth [1][4] Financial Highlights - Revenues for Q1 FY2026 reached CAD 2.7 million, up from CAD 1.2 million in Q1 FY2025 [5] - Total expenses increased to CAD 3.92 million from CAD 1.55 million in Q1 FY2025 [5] - Contract Research Services generated CAD 820,000 in revenue, compared to CAD 380,000 in Q1 FY2025 [5] Operational Highlights - The company delivered its first Self Driving Laboratory (SDL) to the Korean Pharmaceutical BioPharmaceutical Manufacturers' Association (KPBMA) [5] - The proprietary ReCRFT™ process achieved over 99.9% pure Li2CO3 from battery recycling brines, with materials shipped to Cellmine Ltd. and the University of St. Andrews for testing [5] - The company received conditional approval for CAD 3.6 million in government funding for lithium recycling and solid-state battery materials technologies [5]

Core Viewpoint - Telescope Innovations Corp. has authorized the grant of stock options, restricted share units, and the issuance of common shares to settle outstanding fees owed to its CEO [1] Stock Option Grant - The company has granted stock options to a consultant, allowing the acquisition of up to 250,000 common shares at a price of $0.33 per share until December 31, 2030, with vesting occurring quarterly over four months and then annually for three years [2] RSU Grant - A total of 192,000 restricted share units have been granted to three directors as part of their compensation arrangements for 2024 and 2025, valued at $48,000, with similar vesting terms as the stock options [3] Shares for Debt - CEO Henry Dubina will settle $12,000 of outstanding debt through the issuance of 48,000 common shares at a deemed price of $0.25 per share, subject to a four-month hold period [4] Related Party Transaction - The share issuance to Mr. Dubina is classified as a related party transaction, and the company will rely on exemptions from formal valuation and minority approval requirements as the transaction does not exceed 25% of the company's market capitalization [5] Company Overview - Telescope Innovations is focused on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries, utilizing advanced technologies such as flexible robotic platforms and AI software to enhance efficiency and data quality [6]

Core Insights - Telescope Innovations Corp. reported revenues of $5.8 million for the fiscal year ended August 31, 2025, an increase from $4.4 million in FY 2024, while experiencing an Adjusted EBITDA loss of $402,000 compared to a loss of $152,000 in the previous year [1][8]. Operational Highlights - The company achieved significant milestones, including continued progress on the Self-Driving Lab (SDL) program with Pfizer and record sales of DirectInject-LC™ [4][8]. - Telescope Innovations successfully produced battery-grade lithium sulfide using a proprietary low-temperature method, with initial samples shipped to battery industry groups in North America and Asia [8]. Financial Highlights - Total expenses for FY 2025 were $7.3 million, up from $5.8 million in FY 2024 [8]. - The company is strategically reinvesting revenues to enhance research and development (R&D) and commercialization capacity, indicating a focus on long-term growth [1][4].

Core Insights - Telescope Innovations Corp. has successfully installed South Korea's first Self-Driving Lab (SDL) for pharmaceutical research, marking a significant milestone in autonomous R&D [3][4] - The installation was completed in just three weeks, showcasing the company's rapid deployment capabilities and collaboration with the Acceleration Consortium [4][5] - The SDL aims to enhance the efficiency of pharmaceutical innovation by utilizing robotics, inline analytics, and AI to optimize experiments [6][11] Company Achievements - The SDL was delivered to the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) for their AI-focused R&D training center in Seoul [3][4] - The project was supported by two-time Nobel Prize winner Prof. Barry Sharpless, who emphasized the importance of reliable AI in chemical research [7][8] - Telescope's ability to deploy advanced autonomous R&D systems positions the company for further commercial opportunities in various sectors, including industrial chemistry and agriculture [11] Technological Impact - Self-Driving Labs represent a new model for pharmaceutical development, capable of running hundreds of experiments continuously and adjusting parameters in real-time [6][10] - The technology is expected to significantly reduce R&D timelines and costs, potentially cutting years from traditional development processes [6][11] - Telescope Innovations is recognized as a leader in developing advanced SDL systems, which are designed for true closed-loop, autonomous chemical experimentation [6][10] Collaborative Efforts - The SDL installation is a result of nearly a decade-long collaboration between Canadian and Korean universities, industry partners, and government organizations [5][10] - The Acceleration Consortium plays a crucial role in facilitating the commercialization of SDL technology, bridging the gap between research and deployable solutions [9][10] - Initial investments by the Canadian government have catalyzed SDL research, further enhancing the collaboration between academia and industry [10]

Core Insights - Telescope Innovations has been selected by the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) to provide its Self-Driving Lab (SDL) platform for a new R&D facility in Seoul, marking a significant step in Korea's biopharma sector [3][5] - The SDL technology utilizes robotics, inline analytics, and AI to optimize experiments, potentially reducing drug development timelines significantly [4][5] - This initiative is part of KPBMA's broader mission to support R&D and innovation in the pharmaceutical industry, with the SDL serving as a training hub for researchers [7][8] Company Overview - Telescope Innovations is recognized as a leading developer of Self-Driving Lab systems, focusing on scalable manufacturing processes and tools for the pharmaceutical and chemical industries [11] - The company aims to enhance experimental throughput, efficiency, and data quality through its advanced technologies [11] Industry Impact - The deployment of SDLs is expected to accelerate the transition towards automated and digital R&D in Korea, with implications for various sectors including pharmaceuticals, agriculture, and energy [5][9] - The partnership with KPBMA positions Telescope at the forefront of the growing market for lab automation and digital transformation in Asia [8][9]

Core Insights - Telescope Innovations Corp. has been conditionally approved for up to CAD $3.36 million in government funding to advance its lithium processing technologies, announced by Canada's Minister of Energy and Natural Resources during the G7 Energy and Environment Ministers' meeting [1][2]. Funding and Support - The company is receiving up to CAD $319,200 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for demonstrating its lithium carbonate crystallization technology, ReCRFT™, aimed at battery recycling [2]. - An additional CAD $3.04 million has been conditionally approved through Natural Resources Canada's Critical Minerals Research, Development and Demonstration (CMRDD) program to scale up and pilot the DualPure™ process, which focuses on producing high-purity lithium sulphide [2]. Technological Advancements - Telescope Innovations is advancing its lithium carbonate recovery and lithium sulphide synthesis technologies, contributing to the on-shoring of advanced battery materials manufacturing [5]. - The ReCRFT™ technology has progressed from research to demonstration within one year, aligning with the increasing global demand for a circular lithium supply [6]. - The DualPure™ process is also moving towards commercialization, coinciding with the rising demand for high-purity lithium sulphide from global battery manufacturers [6]. Strategic Collaboration - The company is collaborating with international partners under the G7 Critical Minerals Action Plan to enhance critical mineral supply chains, focusing on sustainability and competitiveness [3][4]. Automation and R&D Model - Telescope's intelligent automation laboratory infrastructure supports both lithium refinement programs, enabling rapid iteration and cost-effective development of new chemical processes [7]. - The automation-first R&D model allows for faster transition from proof-of-concept to demonstration and scale-up, generating data-rich insights essential for deployment [7]. Company Overview - Telescope Innovations is a chemical technology company focused on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries, utilizing robotic platforms and AI to improve efficiency and data quality [8].

Core Viewpoint - Telescope Innovations Corp. has entered into agreements to settle outstanding indebtedness through the issuance of 689,654 common shares, indicating a strategic move to manage financial obligations and enhance liquidity [1]. Debt Settlement - The company has agreed to settle CAD $100,000 in outstanding indebtedness with Jason Hein, Chief Technology Officer, through the issuance of 344,827 shares at a deemed price of CAD $0.29 per share [2]. - Additionally, the company will settle CAD $100,000 of a secured loan of CAD $1,200,000, which bears interest at 6.95% per annum and matures on June 1, 2026, through the issuance of another 344,827 shares at the same price [3]. Related Party Transaction - Jason Hein's participation in the debt settlement qualifies as a "related party transaction" under Multilateral Instrument 61-101, with the company relying on exemptions from formal valuation and minority shareholder approval requirements [4]. Regulatory Compliance - All shares issued in the debt settlement will be subject to a statutory hold period of four months and one day, and the completion of the settlement is contingent upon approval from the Canadian Securities Exchange and other regulatory bodies [5]. Company Overview - Telescope Innovations is focused on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries, utilizing advanced technologies such as flexible robotic platforms and artificial intelligence to enhance efficiency and data quality [6].

Core Insights - Telescope Innovations has been selected to join the Arkansas Lithium Technology Accelerator (ALTA), marking a significant step in its engagement with industry leaders for the commercialization of its lithium processing technologies [1][6]. Group 1: ALTA Overview - ALTA connects leading lithium companies such as Standard Lithium, Albemarle, and ExxonMobil with technology enterprises like Telescope to advance innovations in critical mineral processing and battery supply chains [2]. Group 2: Lithium Refining Innovations - Telescope is advancing two proprietary lithium refinement technologies: ReCRFT™, a low capital expenditure method for producing battery-grade lithium carbonate, and DualPure™, a low-temperature method for producing lithium sulfide for solid-state batteries [3]. - ReCRFT™ has successfully processed feedstocks from over 8 lithium production sites across North America, while DualPure™ has produced lithium sulfide samples currently under evaluation by battery industry groups in North America and Asia [3]. Group 3: Engagement Benefits - The engagement with ALTA positions Telescope's technologies for pilot-scale deployment, providing direct access to a network of leading lithium producers for technical collaboration and integration into commercial operations [5]. - Collaborations through ALTA can expedite the validation of Telescope's processes under operational conditions, thereby reducing commercialization risk and accelerating time to market [5]. Group 4: Company Perspective - The CEO of Telescope stated that the invitation to ALTA is timely, as the company's lithium processing technologies are validated across multiple feedstocks, and they are ready to move into piloting with lithium producers [6]. - Arkansas is highlighted as an ideal location for deploying these technologies due to its high-quality resources and community support [6].